FDA Rejects Psychedelic PTSD Therapy

This is a news story, published by The Atlantic, that relates primarily to Lykos Therapeutics news.

Lykos Therapeutics news

For more Lykos Therapeutics news, you can click here:

more Lykos Therapeutics news

mental health treatments news

For more mental health treatments news, you can click here:

more mental health treatments news

The Atlantic news

For more news from The Atlantic, you can click here:

more news from The Atlantic

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like mental health treatments news, you might also like this article about

psychedelic therapy

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest psychedelic drug news, psychedelic drugs news, mental health treatments news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

psychedelic medicine

The Atlantic

•

Psychedelic Medicine Has a Therapy Problem

Summary

Nutrition label

83% Informative

The FDA declined to approve MDMA -assisted therapy for PTSD , instead asking the drugmaker Lykos Therapeutics to conduct another clinical trial to better show that the treatment is safe and effective.

The FDA ’s decision, its first on a psychedelic drug, will likely only delay psychedelic medicine’s official debut in mainstream medicine.

Some experts worry that approval might hinge on dropping the therapy component, turning psychedelics into just more pills to pop.

Lykos ’s approach to therapy isn’t the only option in psychedelic medicine.

A good relationship with a therapist might be all that matters for good outcomes, instead of the precise form of therapy.

Many companies with psychedelic drugs in the regulatory pipeline are trying to minimize therapy as much as possible.

VR Score

Informative language

Neutral language

Article tone

informal

Language

English